ESMO 2023

Updates from ESMO 2023 – TROPION-Lung01

By Dr. Anam Kamal Ascension Providence Hospital TROPION-Lung01: A randomized, phase-3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in…

7 months ago

ESMO 2023 Update – KEYNOTE-671

ESMO 2023 Update - KEYNOTE-671: The First Perioperative Immunotherapy Clinical Trial in Non-Small Cell Lung Cancer Improving Overall Survival Author:…

7 months ago

ESMO 2023 Update – Non-Small Cell Lung Cancer

ESMO 2023 Update – MARIPOSA: Amivantamab + Lazertinib Improves Progression-Free Survival Compared to Osimertinib in EGFR-Mutated, Treatment-Naïve Non-Small Cell Lung…

7 months ago

ESMO 2023 Update – ALINA

ESMO 2023 Update – ALINA: Adjuvant Alectinib Improves Disease-Free Survival in Resected Early-Stage Non-Small Cell Lung Cancer Author: Lei Deng,…

7 months ago

ESMO Updates – October 21 – LIBRETTO-431

LIBRETTO-431: Randomized phase III study of selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive advanced NSCLC  Author: Dr. Anam Kamal Selpercatinib…

7 months ago

ESMO 2023 – October 21 Updates – CheckMate 77T

ESMO 2023 Update – CheckMate 77T: Another Phase 3 Trial of Perioperative Immunotherapy Improving Event-Free Survival for Resectable Stage II-III…

7 months ago